Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib-Enhanced Conditioning for Pediatric and Young Adult Patients With Symptomatic Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation

NCT07252050 is registered in ClinicalTrials.gov with Arkansas Children's Hospital Research Institute as lead sponsor.

NCT NCT07252050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07252050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib-Enhanced Conditioning for Pediatric and Young Adult Patients With Symptomatic Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Lead sponsor
Arkansas Children's Hospital Research Institute
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 8, 2026
Completion date
November 19, 2029
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

graft failure, haploidentical hematopoietic stem cell transplant, haploidentical stem cell transplantation, hematopoetic stem cell transplant, sickle cell disease